1196038-35-3

Basic information

• Product Name: 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid {(S)-2-[3-(4-methoxy-phenyl)-propylamino]-pentyl}-amide
• Synonyms: 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid {(S)-2-[3-(4-methoxy-phenyl)-propylamino]-pentyl}-amide
• CAS NO: 1196038-35-3
• Molecular Weight: 420.942
• Mol File: 1196038-35-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid {(S)-2-[3-(4-methoxy-phenyl)-propylamino]-pentyl}-amide(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid {(S)-2-[3-(4-methoxy-phenyl)-propylamino]-pentyl}-amide(1196038-35-3)
• EPA Substance Registry System: 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid {(S)-2-[3-(4-methoxy-phenyl)-propylamino]-pentyl}-amide(1196038-35-3)

Safety Data

• Hazardous Substances Data: 1196038-35-3(Hazardous Substances Data)

Upstream product

• 1196038-51-3 ((S)-1-aminomethyl-butyl)-carbamic acid tert-butyl ester 
• 1196038-50-2 [(S)-1-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-butyl]-carbamic acid tert-butyl ester 
• 1196038-52-4 ((S)-1-{[(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-amino]-methyl}-butyl)-carbamic acid tert-butyl ester 
• 1196038-13-7 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid ((S)-2-aminopentyl)-amide 
• 20401-88-1 3-(4-methoxyphenyl)propional 
• 5406-18-8 3-(p-methoxyphenyl)-1-propanol 
• 22724-81-8 L-norvalinol 
• 116611-57-5 tert-butyl [(1S)-1-(hydroxymethyl)butyl]carbamate 

Relevant articles and documents

Discovery of a novel chemotype of potent human ENaC blockers using a bioisostere approach. Part 2: α-Branched quaternary amines

We report the synthesis and biological evaluation of a series of novel α-branched pyrazinoyl quaternary amines for their ability to block ion transport via the epithelial sodium channel (ENaC) in human bronchial epithelial cells (HBECs). Compound 12g has an IC50 of 30 nM and is highly efficacious in the Guinea-pig tracheal potential difference (TPD) model of ENaC blockade with an ED50 of 1 μg kg-1 at 1 h. In addition the SAR results demonstrate for the first time the chiral nature of the binding site of human ENaC. As such, pyrazinoyl quaternary amines represent a promising new class of ENaC blockers for the treatment of cystic fibrosis that are structurally distinct from the pyrazinoyl guanidine chemotype found in prototypical ENaC blockers such as amiloride.